Protego Biopharma also presented retrospective data on early NT-proBNP changes as a signal of cardiac response.


Protego Biopharma presented data on AmyLiteDx, a mass spectrometry-based platform for analyzing amyloidogenic immunoglobulin light chains in light chain (AL) amyloidosis. The company also presented a retrospective analysis of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as an early indicator of cardiac response. Both were among five presentations at the International Symposium on Amyloidosis, held Nov 15-18.

According to Protego, current immunoassay-based methods measure circulating light chain concentration but do not directly assess light chain instability. The company describes AmyLiteDx as a next-generation platform that enables deeper characterization and monitoring of unstable, toxic light chains alongside conventional biomarkers.

For laboratories that support hematology and cardiology services, the work reflects interest in measuring the properties of light chains that drive organ damage, not just their quantity.

AL amyloidosis is a rare, life-threatening disease in which abnormal plasma cells produce light chain proteins that can misfold and aggregate. Protego reports that it affects more than 5,100 newly diagnosed patients annually and 28,000 US adults. Injury can occur in organs including the heart and kidneys.

NT-proBNP as an Early Marker of Cardiac Response

A separate retrospective study evaluated NT-proBNP in newly diagnosed patients with Mayo stage II-IIIb AL amyloidosis who were receiving standard-of-care therapy.

NT-proBNP reductions in patients who showed a cardiac organ response at six months were most apparent within the first 28 days. Early cardiac response was associated with improved overall survival over the long term.

Protego says the findings support investigational approaches that can more rapidly and potently address amyloidogenic light chain toxicity to improve rates of early cardiac organ response.

“Cardiac involvement is a major driver of morbidity and mortality in AL amyloidosis,” says Brent J. Warner, MBA, CEO of Protego, in a release. He adds that the company will evaluate in its planned trial “whether this approach can deliver earlier and deeper cardiac responses.”

Therapeutic Data Behind the Diagnostics

The diagnostic and biomarker presentations accompanied data on PROT-001, Protego’s investigational oral small molecule. PROT-001 is designed as a kinetic stabilizer of amyloidogenic light chains that neutralizes their toxicity.

In a Phase 1 study of 102 healthy volunteers, twice-daily oral dosing was generally safe and well tolerated. It also achieved plasma levels associated with sustained ex vivo stabilization of amyloidogenic lambda light chains.

In cell-based studies, amyloidogenic light chains reduced human cardiomyocyte viability by more than 50%, while non-amyloidogenic light chains did not affect viability. PROT-001 restored viability in a dose-dependent manner and selectively suppressed expression of BNP and troponin.

Additional data showed that PROT-001 did not reduce the plasma cell-killing activity of bortezomib or worsen its toxic effects on human heart cells.

The presentations followed FDA clearance for Protego to proceed with SHIELD-AL, a Phase 2/3 trial of PROT-001 in patients with AL amyloidosis.

ID 173861891 © Chernetskaya | Dreamstime.com